DC Chemicals' products qualify for U.S. tariff exemptions. We guarantee no price increases due to customs duties and maintain stable supply, continuing to deliver reliable research solutions to our American clients.
| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DCC2871 | Jwg-115 | Novel BET selective inhibitor, targeting BRD4 |
|
| DCC2872 | Jwh-007 | Potent cannabinoid (CB) receptor agonist |
|
| DCC2873 | Jwu-a021 | Novel potent stimulator of glucagon-like peptide-1 (GLP-1) secretion in vitro, also potently stimulating Ca(2+) influx through TRPA1 cation channels, being one of the most potent non-electrophilic TRPA-1 channel agonists |
|
| DCC2874 | Jxl069 | Novel potent mitochondrial pyruvate carrier (MPC) inhibitor to treat hair loss |
|
| DCC2875 | Jy-1-106 | Novel BH3 α-helix mimetic, inducing apoptosis in a subset of cancer cells (lung cancer, colon cancer and mesothelioma) by disrupting Bcl-xL and Mcl-1 protein-protein interactions with Bak |
|
| DCC2876 | Jyl-1511 | High-affinity partial agonist of the vanilloid receptor |
|
| DCC2877 | Jyl-273 | Potent TRPV1 agonist |
|
| DCC2878 | Jyl-79 | Potent vanilloid receptor (VR1) agonist |
|
| DCC2879 | Jy-xhe-053 | Selective modulator of GABAA receptors containing the α5 subunit |
|
| DCC2880 | Jz-4109 | Novel β-Glucocerebrosidase modulator, promoting dimerization of β-glucocerebrosidase and revealing an allosteric binding site, stabilizing wild-type and N370S mutant GCase and increases GCase abundance in patient-derived fibroblast cells |
|
| DCC2881 | Jz-5029 | Novel irreversible β-Glucocerebrosidase modulator |
|
| DCC2882 | jzad-iv-22 | Inhibitor of all three monoamine transporters |
|
| DCC2883 | Jzp-430 | Potent, highly selective, and irreversible ABHD6 Inhibitor |
|
| DCC2884 | K00135 | Novel potent and selective inhibitor of PIM kinases |
|
| DCC2885 | K00518 | Novel dual CLK1 and CLK3 inhibitor |
|
| DCC2886 | K103 Hydrochloride | Novel inhibitor of peptidoglycan synthesis targeting the lipid II precursor |
|
| DCC2887 | K-14585 | Novel antagonist for proteinase-activated receptor 2 (PAR2) |
|
| DCC2888 | K4610422 | Novel norditerpenoid inhibitor of testosterone-5α-reductase |
|
| DCC2889 | K-8008 | Novel inhibitor of the interaction of the N-terminally truncated RXR |
|
| DCC2890 | K-8012 | Novel inhibitor of the interaction of the N-terminally truncated RXR |
|
| DCC2891 | Kaempulchraol P | Natural anti-inflammatory agent, inhibiting the NF-κB-mediated transactivation of a luciferase reporter gene, IL-6 production, and COX-2 expression |
|
| DCC2892 | Kaempulchraol Q | Natural anti-inflammatory agent, inhibiting the NF-κB-mediated transactivation of a luciferase reporter gene, IL-6 production, and COX-2 expression |
|
| DCC2893 | Kalb001 | Novel mGlu4 ligand |
|
| DCC2894 | Kar425 | Novel antimalarial agent, providing protection to malaria-infected mice |
|
| DCC2895 | Kasugamycin | Antibiotic, binding within the mRNA channel of the 30S subunit and inhibiting protein synthesis |
|
| DCC2896 | Kb130015 | Novel activator of hERG1 potassium channels, blocking native and recombinant hERG1 channels at high voltages, but activating them at low voltages |
|
| DCC2897 | Kbh-a42 | Novel histone deacetylase inhibitor |
|
| DCC2898 | Kbjk557 | Novel Plk1 PBD inhibitor, showing a remarkable in vitro anticancer effect by inducing Plk1 delocalization, mitotic arrest, and apoptosis in HeLa cells |
|
| DCC2899 | Kb-nb165-09 | Selective inhibitor of Protein_kinase_D1>protein kinase D (PKD); Inhibitor of cell adhesion and HIV; Inhibitor of herpes simplex virus type 1 replication |
|
| DCC2900 | Kbp-088 | Novel highly potent dual amylin and calcitonin receptor agonist (DACRA), showing long-lasting improvement of food preference and body weight loss |
|
